Clinilabs Appoints IQVIA Veteran Laura Shannon as CEO to Drive CNS CRO Growth
- Clinilabs, a New York-based CNS-focused CRO, appointed Laura Shannon as CEO; founder Gary Zammit transitions to Executive Chairperson.
- Shannon brings 30+ years of biopharma experience, most recently as EVP and Chief Commercial Officer at IQVIA's U.S. and Canada units.
- The leadership structure pairs commercial expertise with scientific depth to accelerate growth in specialty CNS drug and device development.
Operational Impact
Clinilabs' appointment of an experienced commercial leader from a top-tier CRO signals investment in partnership expansion and operational scaling within the specialty CNS segment, potentially increasing competitive pressure on generalist CROs in neuropsychiatric and sleep-disorder trials.
Source: PharmaSource RSS
BioCytics and LIDE Biotech Partner on PDX Screening for Immuno-Oncology Cell Therapy
- BioCytics (Huntersville, NC) and LIDE Biotech (Shanghai) formed a strategic alliance to develop PDX screening platforms and companion diagnostics for immune-based cancer therapies under a recently executed MOU.
- The pilot project will generate murine PDX models from BioCytics' IRB-approved human biospecimen collection (NCT00571389), enabling in vivo validation of drug resistance and cell death in autologous adaptive immune cell therapy.
- LIDE Biotech operates 2,300+ PDX models across 40+ cancer types and AAALAC-accredited SPF animal facilities; this marks the Shanghai CRO's first U.S. partnership and expansion beyond China.
Operational Impact
LIDE Biotech's first U.S. collaboration extends its PDX translational platform into the North American immuno-oncology market, offering CRO buyers access to patient-derived xenograft screening with rapid miniPDX readouts and ethically sourced biospecimen supply from BioCytics' IRB-governed collection.
Source: PharmaSource RSS